華潤三九(000999.SZ)擬14.2億元收購澳諾製藥100%股權
格隆匯11月27日丨華潤三九(000999.SZ)公佈，為充分發揮核心優勢，豐富品牌和產品線，實現公司戰略目標，公司擬與哈爾濱譽衡藥業股份有限公司(“譽衡藥業”)簽署《關於澳諾(中國)製藥有限公司之股權轉讓合同》，擬收購譽衡藥業持有的澳諾(中國)製藥有限公司(“澳諾製藥”或“目標公司”)100%股權。此次交易價款共計人民幣14.2億元，資金來源為公司自有資金。
澳諾製藥位於保定市高新技術產業開發區，是集生產、研發、銷售於一體的高新技術企業。澳諾製藥現有員工300餘人，擁有通過藥品GMP認證的生產車間，以及現代化的研發中心及檢測中心。澳諾製藥核心產品為葡萄糖酸鈣鋅口服溶液、維生素C咀嚼片、參芝石斛顆粒，其“澳諾”、“金辛金丐特”是兒童補鈣知名品牌。
“澳諾”、“金辛金丐特”牌葡萄糖酸鈣鋅口服溶液是兒童補鈣大產品，具備良好的市場規模和成長性。近年來，該產品及品牌連續位列零售市場鈣補充劑第二位，鈣補充劑藥品市場第一位。零售渠道及醫療渠道市場份額均持續增長(注：數據來源於米內網)。
澳諾製藥口服溶液劑產能10億支，生產、質量管理、供應鏈管理體系基本健全，在生產工藝、成本管理、設備先進性、包材多樣性方面具有一定優勢。
同時，澳諾製藥也在繼續拓展新產品，包括乳果糖口服液、維生素D3滴劑(軟膠囊型)等。
華潤三九致力於成為“大眾醫藥健康產業的引領者”，將以良好體驗的產品和優質的服務，滿足每一個家庭成員從預防、保健、治療、康復全週期、多層次的健康需求，鞏固領導品牌。兒童健康是公司自我診療(CHC)業務重點發展的領域，公司將通過持續豐富產品線、整合行業優質資源，不斷拓展業務，創新和升級產品，提升品牌影響力。此次收購符合華潤三九戰略方向。
澳諾”、“金辛金丐特”是兒童補鈣知名品牌，葡萄糖酸鈣鋅口服溶液是兒童補鈣大產品，具備良好的市場規模和成長性，此次收購可以幫助公司完善自我診療(CHC)品類佈局，可與華潤三九在消費者洞察、品牌運作和終端覆蓋方面的優勢有機結合，發揮良好的協同效應，快速打造兒童健康領導品牌及大品種，並有利於實現領域、人羣等方面的拓展。
澳諾製藥具備一定的市場規模，盈利能力持續穩定，此次收購後，預計可增加公司收益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
